Plain-English translation of NCT07258511 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called works better than another similar injectable treatment for people with multiple myeloma that has come back or stopped responding to standard therapies. Both treatments are designed to target cancer cells in a specific way. The study will help doctors understand which treatment may help patients like you live longer and feel better.
Multiple myeloma is a serious blood cancer, and when it stops responding to standard treatments, options become limited. This medication represents a newer approach to fighting the disease, and researchers want to see if it offers better results than other newer treatments available today.
You likely qualify if…
You likely don't qualify if…
You will receive one of the two treatments as a subcutaneous injection (a shot under your skin) on a regular schedule. You will continue receiving injections until your disease progresses or the side effects become too difficult to manage. Throughout the trial, you'll have regular visits with the study team for blood tests, scans, and check-ins to monitor how you're responding and how you're feeling.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States